Dr. Wang on CAR T-Cell Therapy Resistance in MCL

Video

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma (MCL).

No single treatment can cure every patient, says Wang. Having treatment options in non-Hodgkin lymphoma is necessary, but resistance to these treatments continues to pose a challenge.

Therapies such as rituximab (Rituxan), ibrutinib (Imbruvica) and venetoclax (Venclexta) saw some success in this space, but long-term remission responses were not durable and patients eventually developed resistance to both modalities, Wang says.

The introduction of CAR T-cell therapy as a third treatment saw long-term remission in about 30% to 40% of patients, but a majority developed triple-resistance to chemotherapy, targeted therapy, and eventually, CAR T-cell therapy, he explains.

Personalized medicine may be the answer as it will expose driving resistance mechanisms in individual patients, Wang concludes.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
William Chou, MD, president and chief executive officer of Passage Bio

Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations

William Chou, MD;Noah Stansfield
October 27th 2024
Article

William Chou, MD, president and chief executive officer of Passage Bio, discussed feedback from a recent Type C meeting with the FDA.

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Evaluating Autologous Cord Blood Derived Cells for the Treatment of Preterm Infants

Noah Stansfield
April 8th 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed his lab’s research in the field of neonatal cell therapy.

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital

Standardized Guidelines for Preclinical Testing and Cell Characterization are Critical to Cell Therapy Development

Noah Stansfield
April 3rd 2024
Article

Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital, discussed the importance of preclinical guidelines in the context of neonatal cell therapy.

David Taylor, PhD

New Findings May Help Bolster CRISPR/Cas9 Accuracy

Victoria Johnson
March 4th 2022
Article

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma

Kristi Rosa
June 27th 2021
Article

The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.

Mariana Nacht, PhD

Gene Editing Trial Underway in Pediatric Methylmalonic Acidemia

Victoria Johnson
June 9th 2021
Article

The therapy utilizes LogicBio’s GeneRide technology to insert a corrective copy of the target gene via synthetic AAV vectors.

© 2024 MJH Life Sciences

All rights reserved.